Envoy Medical Reports Third Quarter 2025 Financial and Operational ResultsTransformational quarter puts Envoy Medical in significantly better position as it eliminated $32 million of debt, strengthened its balance sheet, and further expanded its patent portfolio; In addition, subsequent to quarter end, the Company received FDA approval to expand its pivotal clinical trial to the final stage, restarted enrollment, and successfully raised additional capitalNovember 10, 2025 8:00 AM EST | Source: ...